One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Two years of COVID-19 in the MS community: What have we learnt so far?
Ana Zabalza, Alan J Thompson, Xavier Montalban
doi : 10.1177/13524585221099844
Volume 28 Issue 7, June 2022
Focus on neglected features of cognitive rehabilitation in MS: Setting and mode of the treatment
Jessica Podda, Andrea Tacchino, Ludovico Pedull? , Margherita Monti Bragadin, Mario Alberto Battaglia, Giampaolo Brichetto
doi : 10.1177/1352458520966300
Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms
Henrik Heitmann, Till F M Andlauer, Thomas Korn, Mark M?¼hlau, Peter Henningsen, Bernhard Hemmer, Markus Ploner
doi : 10.1177/1352458520972279
Low-dose rituximab should be used for treating MS in resource-limited settings: Yes
Fredrik Piehl, Thomas Mathew
Low-dose rituximab should be used for treating MS in resource-limited settings: No
Farrah J Mateen
Low-dose rituximab should be used for treating MS in resource-limited settings: Commentary
Claudia Cárcamo, Ethel Ciampi
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study
Maria Pia Sormani, Irene Schiavetti, Doriana Landi, Luca Carmisciano, Nicola De Rossi, Cinzia Cordioli, Lucia Moiola, Marta Radaelli, Paolo Immovilli,
Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis
Tatjana Schwarz*, Carolin Otto*, Terry C Jones, Florence Pache, Patrick Schindler, Moritz Niederschweiberer, Felix A Schmidt, Christian Drosten, Victo
Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry
Tim Spelman, Lars Forsberg, Kyla McKay, Anna Glaser, Jan Hillert
Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case–control study of the UK MS Register
Afagh Garjani, Rachael Hunter, Graham R Law, Rodden M Middleton, Katherine A Tuite-Dalton, Ruth Dobson, David V Ford, Stella Hughes, Owen R Pearson, D
COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey
Lauren Uhr, Farrah J Mateen
Effects of voice rehabilitation in people with MS: A double-blinded long-term randomized controlled trial
Valeria Crispiatico, Cinzia Baldanzi, Arianna Napoletano, Laura Tomasoni, Francesca Tedeschi, Elisabetta Groppo, Marco Rovaris, Chiara Vitali, Davide
Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study
Brian M Sandroff, Robert W Motl, Maria Pia Amato, Giampaolo Brichetto, Jeremy Chataway, Nancy D Chiaravalloti, Gary R Cutter, Ulrik Dalgas, John DeLuc
Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology
Zachary Weinstock, Sarah Morrow, Devon Conway, Tom Fuchs, Curtis Wojcik, Mahmut Unverdi, Robert Zivadinov, Bianca Weinstock-Guttman, Grant L Iverson,
Validation of a Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) and comparison with reference batteries
Nicolas Maubeuge, Mathilde SA Deloire, Bruno Brochet, Julie Charr?©-Morin, Aurore Saubusse, Aur?©lie RuetFor the BICAFMS Study Investigators*
Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic
Zo?« YGJ van Lierop*, Alyssa A Toorop*, Wouter JC van Ballegoij, Tom BG Olde Dubbelink, Eva MM Strijbis, Brigit A de Jong, Bob W van Oosten, Bastiaan
Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients
Zoya G Georgieva, Rainer D?§ffinger, Dinakantha Kumararatne, Alasdair J Coles, Claire McCarthy
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
Jeffrey A Cohen, Robert A Bermel, Cynthia I Grossman, Carrie M Hersh, Megan Hyland, Ellen M Mowry, Robert Naismith, Maria L Naylor*, Jacqueline Nichol
Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
Ana Zabalza, Georgina Arrambide, Susana Otero-Romero, Agust?Ân Pappolla, Paula Tagliani, Samuel L?³pez-Maza, Sim?³n C??rdenas-Robledo, Juliana Esperal
Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study
Giovanna S Manzano, Dylan R Rice, Eric C Klawiter, Marcelo Matiello, Rebecca L Gillani, Shahamat S Tauhid, Rohit Bakshi, Farrah J Mateen
ADEM after ChAdOx1 nCoV-19 vaccine: A case report
Virginia Rinaldi, Gianmarco Bellucci, Andrea Romano, Alessandro Bozzao, Marco Salvetti
Demyelinating disorders following COVID-19 vaccination
Marcello Moccia
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica
Edouard Januel, J?©r?´me De Seze, Patrick Vermersch, Elisabeth Maillart, Bertrand Bourre, Julie Pique, Xavier Moisset, Caroline Bensa, Adil Maarouf, J
MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination
Larissa Dams, Markus Kraemer, Jana Becker
MOG antibody–associated longitudinal extensive myelitis after Oxford-Astra Zeneca’s COVID-19 vaccination
Sarah Wright
International Multiple Sclerosis Cognition Society Meeting Bordeaux, France, May 18-19 2022
